NEW YORK (GenomeWeb News) — Accelr8 Technology is working with the Denver Health Medical Center in a study aimed at early identification of a deadly hospital-acquired infection, the company said today.
The company also said that it has filed a plan with the New York Stock Exchange and Alternext for compliance with Alternext's listing rules. The NYSE notified the company recently that it was not in compliance with NYSE Alternext rules because it has stockholder equity of less than $6 million, it has had losses from continuing operations, and net losses in its five most recent fiscal years. The company did not provide details of the plan to regain compliance.
Accelr8, which develops rapid pathogen identification technologies, has supplied DHMC with analytical instrumentation and methods to study intensive care patients who are at risk for contracting ventilator-associated pneumonia.
The goal of the research is to evaluate methods for "substantially reducing" the time it takes to identify bacteria in the lungs, so that patients may be treated before they show pneumonia symptoms. Culturing for this pathogen generally takes between 48 and 72 hours, the company said, but it expects its methods can produce a test to do the job in less than eight hours.
Researchers will compare two surveillance methods for at-risk patients, one using standard culturing and the other using Accelr8's methods, which they suspect will generate an early diagnosis by providing results one or two days sooner.
DHMC is receiving funding for the study under a Team Science Award from the Colorado Clinical and Translational Sciences Institute.
Financial terms of the agreement were not released.
Last May, Accelr8 reached an agreement with Becton Dickinson giving BD an option to exclusively license Accelr8's infectious disease diagnostics IP, while Accelr8 would retain the right to commercialize the technology for other applications.